TrustBank Takes Position in Amgen Inc. $AMGN

TrustBank purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,377 shares of the medical research company’s stock, valued at approximately $778,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Roundview Capital LLC raised its position in Amgen by 18.4% during the fourth quarter. Roundview Capital LLC now owns 886 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 138 shares in the last quarter. Flputnam Investment Management Co. raised its position in Amgen by 2.2% during the fourth quarter. Flputnam Investment Management Co. now owns 55,293 shares of the medical research company’s stock valued at $18,098,000 after purchasing an additional 1,169 shares in the last quarter. Terril Brothers Inc. acquired a new position in Amgen during the fourth quarter valued at approximately $229,000. Integrity Alliance LLC. raised its position in Amgen by 57.5% during the fourth quarter. Integrity Alliance LLC. now owns 10,765 shares of the medical research company’s stock valued at $3,524,000 after purchasing an additional 3,932 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its position in Amgen by 6.0% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 1,998 shares of the medical research company’s stock valued at $654,000 after purchasing an additional 113 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $335.94 on Wednesday. The firm’s fifty day moving average price is $343.92 and its two-hundred day moving average price is $345.13. The stock has a market cap of $181.30 billion, a PE ratio of 23.38, a PEG ratio of 3.41 and a beta of 0.44. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research analyst reports. Barclays initiated coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. The Goldman Sachs Group boosted their price objective on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Piper Sandler lowered their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $355.19.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.